Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts

British Journal of Surgery

Volumn 96, Issue 7, 2009, Pages 809-816

  Silberhumer, G R ^a   Zakian, K ^a   Malhotra, S ^a   Brader, P ^a   Gonen M ^a   Koutcher, J ^a   Fong, Y ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NV 1020; ONCOLYTIC VIRUS; PHOSPHOETHANOLAMINE; PHOSPHORUS 31; PHOSPHORYLCHOLINE; DIAGNOSTIC AGENT; PHOSPHOLIPID; PHOSPHORUS; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIROTHERAPY; ANIMAL; CANCER TRANSPLANTATION; COLORECTAL TUMOR; ESCHERICHIA COLI; GENE VECTOR; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; METABOLISM; METHODOLOGY; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ESCHERICHIA COLI; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; PHOSPHOLIPIDS; PHOSPHORUS ISOTOPES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 67650076199     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6604     Document Type: Article

References (57)

1. Gross C, Andersen M, Krumholz H, McAvay G, Proctor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA 2006; 296: 2815-2822.
2. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49: 231-255.
3. Adam R, Vinet E. Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol 2004; 15(Suppl 4): iv103-iv106.
4. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005; 23: 8490-8499.
5. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224: 323-329.
6. Bennett JJ, Kooby DA, Delman K, McAuliffe P, Halterman MW, Federoff H et al. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000; 78: 166-174.
7. Woo Y, Adusumilli PS, Fong Y. Advances in oncolytic viral therapy. Curr Opin Investig Drugs 2006; 7: 549-559.
8. Hingorani M, White CL, Agrawal VK, Vidal L, Melcher A, Harrington KJ. Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting? Curr Cancer Drug Targets 2007; 7: 389-409.
9. Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006; 17: 1241-1253.
10. Fong Y, Kemeny N, Jarnagin W, Stanziale S, Guilfoyle B, Gusani N et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc Am Soc Clin Oncol 2002; 21: 8a.
11. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859-866.
12. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-874.
13. Kooby D, Carew J, Halterman M, Mack J, Bertino J, Blumgart L et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999; 13: 1325-1334.
14. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12: 413-439.
15. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003; 90: 525-533.
16. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001; 61: 3599-3603.
17. Cullis P, Hope M. Physical properties and functional roles of lipids in membranes. In Biochemistry of Lipids, Lipoproteins, and Membranes, Vance DE, Vance J (eds). Elsevier Science: Amsterdam, 1991; 1-41.
18. Cai H, Erhardt P, Troppmair J, Diaz-Meco MT, Sithanandam G, Rapp UR et al. Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction. Mol Cell Biol 1993; 13: 7645-7651.
19. Noguchi M, Rose DP, Earashi M, Miyazaki I. The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology 1995; 52: 265-271.
20. Barzilai A, Horowitz A, Geier A, Degani H. Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study. Cancer 1991; 67: 2919-2925.
21. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 1996; 16: 1393-1397.
22. 31P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy. Br J Cancer 1991; 63: 953-958.
23. 31P nuclear magnetic resonance spectroscopy. Cancer Res 1994; 54: 4885-4891.
24. 31P nuclear magnetic resonance measurements of metabolic changes post radiation. Cancer Res 1995; 55: 1248-1254.
25. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
26. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602-614.
27. Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC et al. The development of gene therapy for the treatment of cancer. Ann Surg 1993; 218: 455-463.
28. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35-43.
29. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003; 95: 1624-1633.
30. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
31. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase no. 5, version 20. IARC Press: Lyons, 2004.
32. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
33. Grothey A. Biological therapy and other novel therapies in early-stage disease: are they appropriate? Clin Cancer Res 2007; 13: 6909s-6912s.
34. Derubertis BG, Stiles BM, Bhargava A, Gusani NJ, Hezel M, D'Angelica M et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007; 14: 590-597.
35. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17: 1214-1224.
36. Shillitoe EJ, Pellenz C. Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice. Clin Cancer Res 2005; 11: 3109-3116.
37. Goldstein DJ, Weller SK. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol 1988; 62: 2970-2977.
38. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166: 41-51.
39. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989; 173: 276-283.
40. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26: 541-553.
41. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
42. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci U S A 1996; 93: 11 307-11 312.
43. Chou J, Chen JJ, Gross M, Roizman B. Association of a M(r) 90 000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5-mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A 1995; 92: 10 516-10 520.
44. He B, Gross M, Roizman B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 1997; 94: 843-848.
45. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-1266.
46. Chou J, Roizman B. The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A 1992; 89: 3266-3270.
47. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc Natl Acad Sci U S A 2000; 97: 6097-6101.
48. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002; 9: 935-945.
49. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5: 303-324.
50. 31P MRS of experimental tumours. NMR Biomed 1993; 6: 345-365.
51. 31P measurements of response to treatment. NMR Biomed 1998; 11: 314-340.
52. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000; 2: 166-189.
53. 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn Reson Med 1992; 25: 30-44.
54. 31P MRS in situ. Magn Reson Med 1989; 10: 125-134.
55. 31P NMR spectroscopy. J Biol Chem1987; 262: 14 875-14 878.
56. Freyer JP, Schor PL, Jarrett KA, Neeman M, Sillerud LO. Cellular energetics measured by phosphorous nuclear magnetic resonance spectroscopy are not correlated with chronic nutrient deficiency in multicellular tumor spheroids. Cancer Res 1991; 51: 3831-3837.
57. Mintz A, Wang L, Ponde DE. Comparison of radiolabeled choline and ethanolamine as probe for cancer detection. Cancer Biol Ther 2008; 7: 742-747.